2025-05-16

Congratulations! The third phase of Qingdao Baheal Pharmaceutical project has officially started operation, taking the high-end formulation production capacity to a new level.

On May 16, 2025, Qingdao Baiyang Pharmaceutical Co., Ltd., a subsidiary of Baiyang Pharmaceutical (301015.SZ), held the relocation ceremony for the Phase III construction project. Zhu Xiaowei, Director of Baiyang Pharmaceutical Group, Vice President of Baiyang Pharmaceutical, and Chairman of Baiyang Pharmaceutical; Hao Yu, Vice President of Park Operations of Baiyang Pharmaceutical Group; Zheng Aiju, General Manager of Qingdao Baiyang Pharmaceutical; along with other leaders, guests, and colleagues from Qingdao Baiyang Pharmaceutical attended the event to witness this important moment together.

+

2025-03-03

Shanghai Huanghai Pharmaceutical's "Fuzheng Huayu Tablets" Granted Canadian Market Authorization——A New Milestone in the Globalization of Traditional Chinese Medicine

Recently, the star product "Fuzheng Huayu Tablets" from Shanghai Huanghai Pharmaceutical Co., Ltd., a subsidiary of Shanghai Baheal Pharma Co., Ltd., has officially received a product license from Canada’s Natural and Non-Prescription Health Products Directorate (NNHPD) under Health Canada. This achievement underscores the company’s breakthrough in the inheritance and innovation of traditional Chinese medicine (TCM) and is poised to accelerate the global expansion of Fuzheng Huayu.

+

2025-01-04

Good news! The Danshen Tablets (180 tablets) of Shanghai Huanghai Pharmaceutical won the bid to collect traditional Chinese patent medicines and simple preparations nationwide, bringing good news to patients

On December 31, 2024, the Shuanghai brand Danshen tablets (180 tablets) produced by Shanghai Huanghai Pharmaceutical, a subsidiary of Shanghai Baiyang Pharmaceutical, passed strict review and fierce competition, and won the bid for centralized procurement of the National traditional Chinese patent medicines and simple preparations Purchasing Alliance led by Hubei Province, which means that more patients can enjoy this high-quality medical resource at a more affordable price, which is a solid step on the road of fulfilling our social responsibility.

+

2024-10-25

Good News | Baheal Pharmaceutical's Parent Company Baheal Medicine Receives Two "Value" Honors in the Capital Market

Recently, two major awards in the domestic capital market—the "Listed Company Golden Bull Award" and the "China Listed Company Value Selection" list—were announced one after another. With outstanding performance and excellent value return capability, Baiyang Pharmaceutical (301015.SZ) stood out among thousands of listed companies, winning the "2023 Golden Bull Most Investment-Worthy" and "Top 50 Growth Enterprise Market Listed Companies by Value" awards, demonstrating the capital market's high recognition of the company in corporate management, value return, development potential, and other aspects.

+

2024-02-21

Huanghai Pharmaceutical, a subsidiary of Baheal Pharmaceutical, was awarded the title of "Top 100 Enterprises with Economic Contributions in Baoshan District, Shanghai in 2023"

At the 2024 Baoshan District Optimizing Business Environment and Investment Promotion Conference held recently, Shanghai Baheal Pharmaceutical Co., Ltd. (referred to as "Baheal Pharma"), a wholly-owned subsidiary of Shanghai Huanghai Pharmaceutical Co., Ltd. (hereinafter referred to as "Huanghai Pharmaceutical"), was awarded the title of "Top 100 Economic Contributing Enterprises of Baoshan District in 2023" for its contributions to the economic and social development of the entire region.

+
< 12 >